Healthcare
Live Price
Offline$8.77
+0.00% today
Window Change
-7.10%
Window
May 28, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 28, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shionogi & Co., Ltd. (SGIOY) is a Healthcare stock with a market cap of $2.66T and listed on OTC. The stock last traded around $8.77 and down 7.1% across the available one-year price window (May 28, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +0.7%, EPS growth of +7.6%, a dividend yield of 2.3%. What stands out right now is revenue +0.7%, EPS +7.6%, free cash flow +41.5% with operating margin 35.0% and ROIC 8.5%. The dividend is present but secondary, with a yield around 2.3%. Valuation is more restrained than many high-expectation growth names at P/E 13.7 and price/sales 5.7. Stock Foundry combines SGIOY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGIOY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGIOY Max Drawdown
-9.32%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGIOY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$297.2B
-11.3% YoY
FY Net Income
$111.9B
-2.0% YoY
Free Cash Flow
$76.1B
+7.9% YoY
Revenue Growth
+0.7%
EPS Growth
+7.6%
Gross Margin
84.3%
Net Margin
41.9%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 438.3B | 435.1B | 426.7B | 335.1B | 297.2B |
| Gross Profit | 370.3B | 377.5B | 364.4B | 279.7B | 244.7B |
| Operating Income | 159.8B | 171.5B | 160.6B | 110.3B | 117.4B |
| EBITDA | 230.7B | 217.8B | 176.4B | 143.4B | 158.7B |
| Net Income | 170.4B | 162.0B | 185.0B | 114.2B | 111.9B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 374.8B | 358.1B | 309.2B | 254.4B | 276.2B |
| Total Assets | 1535.3B | 1416.9B | 1311.8B | 1150.6B | 999.0B |
| Total Liabilities | 172.8B | 164.4B | 189.9B | 157.3B | 134.4B |
| Shareholder Equity | 1361.9B | 1235.3B | 1100.0B | 975.7B | 846.1B |
| Total Debt | 21.9B | 11.6B | 9.4B | 6.7B | 8.0B |
| Net Debt | -352.9B | -346.5B | -299.8B | -247.7B | -268.2B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
109.0B
+6.8% YoY
Capital Expenditures
32.9B
-4.4% YoY
Free Cash Flow
76.1B
+7.9% YoY
Key ratios
Gross Margin
84.3%
Operating Margin
35.0%
Net Margin
41.9%
ROE
13.7%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.